CARY STREET PARTNERS FINANCIAL LLC
Position in CADL — Candel Therapeutics, Inc.
CIK 1475045
RICHMOND, VA
Position in CADL
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$443,930
New position
Shares Held
43,100
first reported quarter
Ownership
0.059%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#2
of 6 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026CARY STREET PARTNERS FINANCIAL LLC holds $16,295,157 across 13 Biotechnology names. CADL ranks #6 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
22,571 | $11,211,692 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
20,445 | $1,600,230 | |
| 3 | DFTX |
Definium Therapeutics, Inc.
|
15,582 | $732,977 | |
| 4 | PGEN |
Precigen, Inc.
|
87,593 | $499,280 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
6,250 | $465,500 | |
| 6 | CADL |
Candel Therapeutics, Inc.
This page
|
43,100 | $443,930 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
3,645 | $355,314 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
986 | $280,980 |
All Filings in CADL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $443,930 | 43,100 | Shares | Defined | 2026-07-17 | |
| No filing history on record for this holder in this stock. | ||||||